本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 证券代码：300015 证券简称：爱尔眼科 公告编号：2025-086 爱尔眼科医院集团股份有限公司 关于召开 2025 年第三次临时股东大会的通知 1、股东会届次：2025 年第三次临时股东大会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 27 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 27 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2025 年 11 月 27 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日： ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2025-082 爱尔眼科医院集团股份有限公司 第六届董事会第四十四次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届董事会第四十 四次会议于 2025 年 11 月 10 日以通讯表决的方式召开，会议通知于 2025 年 11 月 5 日以邮件方式送达，会议由董事长陈邦先生召集主持，应到董事 7 人，实到 董事 7 人，会议的召开符合《公司法》和《公司章程》的有关规定，会议合法、 有效。经审议，本次会议一致通过如下议案： 一、《关于公司董事会换届选举暨提名第七届董事会非独立董事候选人的议 案》 鉴于公司第六届董事会任期届满，根据《公司法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律法规及《公司章程》的有关规定，公司董事会提名陈邦先 生、李力先生、吴士君先生为公司第七届董事会非独立董事候选人，候选人简历 详见公司披露于巨潮资讯网（http://www.cninfo.com ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-083 爱尔眼科医院集团股份有限公司 关于 2025 年中期分红预案的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 11 月 10 日召 开第六届董事会第四十四次会议，审议通过了《关于 2025 年中期分红预案的议案》， 现将相关内容公告如下： 一、本次中期分红预案基本情况 根据公司 2025 年第三季度财务报表（未经审计），公司 2025 年 1-9 月实现 归属于母公司所有者净利润 3,114,740,426.82 元，母公司实现的净利润为 3,773,189,745.80元。截至 2025 年 9 月 30 日，母公司累计可供分配利润为 7,902,128,430.31 元。 根据中国证监会鼓励上市公司现金分红及给予投资者稳定、合理回报的指导意 见，并在符合利润分配原则，保证公司正常经营和长远发展的前提下，根据《公司 法》和《公司章程》的相关规定，本次中期分红预案如下： 公司拟以扣除回购专户股份数量后的股本 9,294,03 ...

Core Viewpoint - The company plans to distribute a cash dividend of 0.8 yuan (including tax) for every 10 shares to all shareholders, totaling 744 million yuan, based on a share capital of 9.294 billion shares after deducting the number of shares repurchased [1] Group 1 - The total cash dividend to be distributed amounts to 744 million yuan [1] - The dividend distribution will not include any bonus shares or capital reserve fund transfers [1] - The base for the dividend distribution is set at 9.294 billion shares after accounting for repurchased shares [1]

Group 1 - The core point of the news is the significant block trade of Aier Eye Hospital on November 10, with a transaction volume of 850,000 shares and a transaction amount of 10.88 million yuan, at a price of 12.80 yuan, which is a 2.65% premium over the closing price of the day [2][3] - The buyer of the block trade was GF Securities Co., Ltd., and the seller was Everbright Securities Co., Ltd. [2][3] - In the last three months, Aier Eye Hospital has recorded a total of six block trades, with a cumulative transaction amount of 61.96 million yuan [2] Group 2 - The closing price of Aier Eye Hospital on the day of the block trade was 12.47 yuan, reflecting a 3.40% increase, with a turnover rate of 1.58% and a total transaction amount of 1.544 billion yuan [2] - The net inflow of main funds for the day was 291 million yuan, and the stock has increased by 2.13% over the last five days, with a total net inflow of 2.335 million yuan [2] - The latest margin financing balance for Aier Eye Hospital is 2.521 billion yuan, with a decrease of 6.2262 million yuan over the last five days, representing a decline of 0.25% [3]

Group 1 - The core point of the article highlights the recent performance of Aier Eye Hospital, which saw a stock price increase of 3.40% to close at 12.47 yuan, with a significant block trade occurring [1] - A total of 850,000 shares were traded in a block transaction, amounting to 10.88 million yuan, with a premium rate of 2.65% [1] - The buyer was from GF Securities Co., Ltd., while the seller was from Everbright Securities Co., Ltd. [1] Group 2 - Over the past three months, Aier Eye Hospital has recorded six block trades with a cumulative transaction value of 61.96 million yuan [1] - In the last five trading days, the stock has increased by 2.13%, with a net inflow of 19.23 million yuan from major funds [1]

Core Insights - The medical services sector experienced a rise of 0.89% on November 10, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.87, with an increase of 8.94% and a trading volume of 99,000 shares, amounting to a transaction value of 330 million [1] - Tongce Medical (600763) saw a closing price of 44.51, up 5.00%, with a trading volume of 174,500 shares and a transaction value of 769 million [1] - Puri Eye Hospital (301239) closed at 38.73, up 4.96%, with a trading volume of 38,500 shares and a transaction value of 148 million [1] - Other notable performers include Hite Bio (300683) with a 4.85% increase, and Aier Eye Hospital (300015) with a 3.40% increase [1] Capital Flow Analysis - The medical services sector saw a net outflow of 185 million from institutional investors, while retail investors contributed a net inflow of 84.71 million [2] - Major stocks like Aier Eye Hospital (300015) experienced a net inflow of 300 million from institutional investors, despite a significant outflow from retail investors [3] - Tongce Medical (600763) had a net inflow of 115 million from institutional investors, but also faced outflows from retail investors [3]

Core Viewpoint - Aier Eye Hospital's stock price has shown fluctuations, with a recent increase of 2.07% to 12.31 CNY per share, while the company has experienced a year-to-date decline of 5.97% [1] Financial Performance - For the period from January to September 2025, Aier Eye Hospital achieved a revenue of 17.484 billion CNY, representing a year-on-year growth of 7.25%. However, the net profit attributable to shareholders decreased by 9.76% to 3.115 billion CNY [2] - Cumulative cash dividends since Aier Eye Hospital's A-share listing amount to 7.12 billion CNY, with 3.6 billion CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Aier Eye Hospital reached 344,800, an increase of 0.27% from the previous period. The average number of circulating shares per shareholder decreased by 0.27% to 23,002 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 163 million shares, which decreased by 29.98 million shares compared to the previous period [3]

Core Viewpoint - The Medical Health R Index (480016) closed at 7535.01 points, down 0.39%, with a trading volume of 21.869 billion yuan and a turnover rate of 0.89% on November 7 [1] Group 1: Index Performance - The index had 26 stocks rising, with Xinhecheng leading at a 4.9% increase, while 23 stocks fell, with Zaiqing Pharmaceutical leading the decline at 4.35% [1] - The top ten constituent stocks of the Medical Health R Index are primarily in the pharmaceutical and medical sectors, with notable weights and market capitalizations [1] Group 2: Key Constituents - WuXi AppTec (sh603259) holds a weight of 13.66% with a market cap of 282.98 billion yuan, closing at 94.84 yuan, down 0.89% [1] - Hengrui Medicine (sh600276) has an 11.00% weight, a market cap of 408.72 billion yuan, and closed at 61.58 yuan, down 1.35% [1] - Mindray Medical (sz300760) has a weight of 7.57%, a market cap of 249.51 billion yuan, and closed at 205.79 yuan, down 0.27% [1] - Other notable constituents include United Imaging Healthcare (sh688271), Pianzai Shou (sh600436), and Xinhecheng (sz002001), which saw a 4.9% increase [1] Group 3: Capital Flow - The Medical Health R Index constituents experienced a net outflow of 240 million yuan from institutional investors and 119 million yuan from retail investors, while retail investors saw a net inflow of 359 million yuan [1] - Specific stocks like Huazhong Pharmaceutical (000999) and Yuyue Medical (002223) showed significant net inflows and outflows among different investor types [2]

Summary of Aier Eye Hospital Conference Call Company Overview - **Company**: Aier Eye Hospital (300015.SZ) - **Industry**: Healthcare, specifically ophthalmology services Key Points Refractive Business Performance - The refractive business experienced lower-than-expected volume growth, but the Average Selling Price (ASP) increased due to a higher mix of premium procedures [1][3] - Premium procedures now account for approximately 40% of total refractive surgeries, contributing to stable pricing and reduced price competition [6][9] - The company noted a year-over-year growth of about 10% in the first three quarters and October, primarily driven by premium surgical procedures [6] Cataract Business Challenges - The cataract business faced significant pressure, with volumes declining by high-single to low-double digits, despite stable revenue due to the acquisition of 87 hospitals [7][9] - ASP for cataract procedures rebounded by approximately 5-6% year-over-year, driven by increased adoption of functional lenses and self-pay procedures [7] - The company is promoting functional lenses and self-pay projects to mitigate reliance on medical insurance, although this transition will take time [7] Financial Outlook - The company anticipates short-term margin pressure due to new hospital costs and rising labor expenses, with gross and net margins expected to remain flat or slightly decline [8] - Aier Eye Hospital is focusing on operational optimization and expansion of self-pay services to achieve steady growth [8] - The company has designated the next three years as "years of execution," emphasizing refined operations and profitability recovery [8] Investment Thesis - Aier Eye Hospital is positioned to capture increasing demand from the 50+ demographic, particularly in premium and out-of-pocket treatments [9] - The current valuation is seen as offering an attractive risk-reward profile, with a target price of Rmb15, representing a 24.5% upside from the current price of Rmb12.05 [2][12] Risks - Key risks include a slower-than-expected premiumization trend in cataract surgery, intensifying price competition in refractive surgery, and potential pricing pressure from policies related to OK lenses [12] Additional Insights - The company is optimistic about future growth despite acknowledging the challenging macroeconomic environment in China [8] - The share of public service applicants in refractive surgeries has increased to about one-third, indicating a shift in patient demographics [6] This summary encapsulates the critical insights from the conference call, highlighting the performance, challenges, and strategic outlook of Aier Eye Hospital in the ophthalmology sector.